With just six weeks to go until the prestigious PharmaTimes Marketer of the Year closes for entry, marketers at all levels of their career are looking forward to taking part in the 25th anniversary celebrations.
News
Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.
Kisqali wins speedy US breast cancer nod
Novartis’ Kisqali has been approved for breast cancer in the US less than one month after being filed with the US Food and Drug Administration.
Four pharmas named for breaching ABPI Code of Practice
Martindale Pharma, Pierre Fabre, Janssen and Pharmasure have all been named in advertisements for breaching the Association of the British Pharmaceutical Industry’s Code of Practice.
Dementia accounts for 12.7 percent of deaths
New data has revealed that Alzheimer’s disease and other forms of dementia accounted for 12.7 percent of all deaths in England and Wales last year.
Novartis bags rights to Galapagos/MorphoSys atopic dermatitis drug
Novartis has signed an exclusive global license agreement with Galapagos and MorphoSys for MOR106, a novel antibody directed against IL-17C.
NICE calls for quicker treatment of kidney stone patients in pain
The National Institute for Health and Care Excellence has released new draft guidelines calling for faster treatment of patients with kidney stones experiencing severe pain.
Record numbers taking part in life sciences industry research
The number of people taking part in NHS clinical research studies sponsored by the life sciences industry has risen dramatically over the last year, show new figures by the National Institute for Health Research (NIHR).
US approves Janssen’s HIV pill Symtuza
Janssen’s Symtuza has been approved US regulators as the first and only complete, darunavir-based single-tablet regimen for the treatment of HIV in adults.
MPs vote for UK to remain part of EMA
MPs have voted 305-301 that the UK should negotiate to remain part of the European Medicines Agency following Brexit.
Vertex mulls over NHS England’s offer for CF drugs
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condition.
Roche’s antiviral hits flu targets in PhIII trial
Roche says its investigational flu drug baloxavir marboxil, in-licensed from Japan’s Shionogi, has met key goals in a late-stage trial.
Pfizer kicks off PhIII programme for haemophilia B gene therapy
Pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B.
UK panel says human embryo editing ‘morally permissible’
An independent ethics panel in the UK has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”.
NICE issues cerebral palsy guideline for adults
The National Institute for Health and Care Excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy.
